<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820064</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.303</org_study_id>
    <nct_id>NCT02820064</nct_id>
  </id_info>
  <brief_title>Effects of Hypoxia and Inflammation on Citrulline Synthesis by Ornithine Transcarbamylase in Human Enterocytes</brief_title>
  <acronym>HYPOCITRE</acronym>
  <official_title>Effects of Hypoxia and Inflammation on Citrulline Synthesis by Ornithine Transcarbamylase in Human Enterocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AGIR à Dom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic systemic hypoxia and
      low-grade inflammation as well as by an alteration of arginine (ARG) metabolism. As ARG is
      synthetized from circulating citrulline (CIT), an alteration of CIT homeostasis, particularly
      its production by ornithine transcarbamylase (OCT) in small intestine could be involved. We
      hypothesized that hypoxia +/- inflammation, classically associated to COPD, has effects on
      OCT regulation in enterocytes.

      This study aims at exploring the effects of hypoxia and inflammation on the production of
      citrulline by ornithine transcarbamylase (OTC) activity in enterocytes from explant cultures
      of duodenal tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Citrulline is an amino-acid almost exclusively released by the small intestine after its
      synthesis from glutamine by the OTC in enterocytes. Citrulline from the small intestine is
      released into the portal vena and, because it does not enter hepatocytes, it reaches the
      systemic circulation to be metabolized in arginine by kidneys. By this way, is an important
      source of endogenous ARG. Moreover, evidence suggests that circulating citrulline could have
      a direct action on the regulation of muscle protein synthesis. Therefore, the administration
      of citrulline might be an interesting nutritional strategy to preserve or restore muscle mass
      and function. Muscle mass is a determinant of respiratory function and muscle weakness
      explains for a large part morbidity and mortality in patients suffering from Chronic
      Obstructive Pulmonary Disease (COPD).

      Evidence suggests that citrulline plasmatic levels would be lower in several states involving
      systemic inflammation and hypoxia. Indeed, it has been observed in rats that hypoxia leads to
      a sharp decline in plasma CIT concentration and also in human (hypocitrullinemia has been
      observed in Intensive Care Unit patients and in subjects suffering from sepsis and trauma)
      but the cause of relationship is not yet established. Therefore, it may be supposed that a
      decreased plasma CIT level could be responsible for a decrease in de novo ARG synthesis
      leading to an impairment of NO production (endothelial dysfunction) in these pathological
      situations.

      Because chronic hypoxia and systemic inflammation are both systemic traits of patients
      suffering from COPD, the fact that hypoxia and/or systemic inflammation might directly affect
      OCT, decreasing intestinal citrulline production which, in turn, could contribute to
      endothelial dysfunction and muscle weakness is considered.

      In order to explore this hypothesis, the potential consequences of hypoxia and inflammation
      (alone or in association) on citrulline synthesis by the OCT in human enterocytes will be
      determined, thanks to an &quot;explant&quot; culture model of duodenal tissue. Duodenal biopsies will
      be removed during oesophago-gastro-duodenoscopies performed in the Hepato-gastro-enterology
      unit of Grenoble University Hospital, among patients expected to undergo a gastroscopy for
      any diagnostic purpose. 30 patients will be selected during a period of 6 months. After
      complete information and written agreement, 8 biopsy specimens will be removed from the
      duodenum of each patient and processed for organ culture.

      Then, duodenal biopsies will be incubated in the presence or not of cytokines and exposed or
      not to hypoxia. Indeed, 4 groups will be constituted: a control group (no stimulus), a group
      exposed to hypoxic conditions, a group exposed to inflammatory conditions (cytokines) and a
      group exposed to both hypoxic an inflammatory conditions.

      As primary endpoint, for each group, the OTC activity and the citrulline production in the
      culture medium will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OCT activity in biopsy specimens</measure>
    <time_frame>OCT activity in biopsies after incubation</time_frame>
    <description>OCT activity in duodenal biopsy specimens will be measured at the end of the incubation period and compared between the 4 different groups (standard/inflammatory/hypoxic:inflammatory+hypoxic conditions)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypoxia</condition>
  <condition>Inflammation</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>only one arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>duodenal biopsy during gastroduodenal endoscopy</intervention_name>
    <description>Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.</description>
    <arm_group_label>only one arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Digestive disease known or suspected which justify an oeso-gastro-endoscopy with
             digestive biopsies, excepted a disease with duodenal localization known or strongly
             suspected.

          -  Gastroscopy performed under general anaesthesia

          -  Patient's written agreement obtained

        Non inclusion-criteria:

          -  Age &lt; 18

          -  Therapeutical endoscopy (that is to say when a therapeutical act will be performed as
             balloon dilation, digestive or biliary prosthesis, drainage, diverticulotomy,
             polypectomy, variceal ligation...) either expected or

          -  Duodenal pathology (known or strongly suspected with the clinical and biological
             elements)

          -  Duodenal biopsies are not allowed to be performed: vascular lesions, digestive
             haemorrhage, clotting disorder.

          -  Antiplatelet drug and anticoagulant drug

          -  Lack of written agreement

          -  Subjects hospitalized in an emergency state or without agreement

          -  Subjects who cannot be contacted in emergency.

        Exclusion criteria:

        subjects will be excluded from the study:

          -  if an unexpected therapeutic act has to be performed during the endoscopy

          -  if duodenal duodenal atrophy or lesions are discovered during the endoscopy

          -  if duodenal lesions are discoverd at the histological examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Fontaine, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of clinical Nutrition-Grenoble University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric FONTAINE, Professor</last_name>
    <email>efontaine@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Fontaine, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Tuvignon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eyraud Pierre Yves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu Nicolas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Picot Audrey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Moinard C, Cynober L. Citrulline: a new player in the control of nitrogen homeostasis. J Nutr. 2007 Jun;137(6 Suppl 2):1621S-1625S. doi: 10.1093/jn/137.6.1621S. Review.</citation>
    <PMID>17513438</PMID>
  </reference>
  <reference>
    <citation>Windmueller HG, Spaeth AE. Source and fate of circulating citrulline. Am J Physiol. 1981 Dec;241(6):E473-80.</citation>
    <PMID>7325229</PMID>
  </reference>
  <reference>
    <citation>Breuillard C, Cynober L, Moinard C. Citrulline and nitrogen homeostasis: an overview. Amino Acids. 2015 Apr;47(4):685-91. doi: 10.1007/s00726-015-1932-2. Epub 2015 Feb 13. Review.</citation>
    <PMID>25676932</PMID>
  </reference>
  <reference>
    <citation>Osowska S, Moinard C, Neveux N, Loï C, Cynober L. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut. 2004 Dec;53(12):1781-6.</citation>
    <PMID>15542514</PMID>
  </reference>
  <reference>
    <citation>Osowska S, Duchemann T, Walrand S, Paillard A, Boirie Y, Cynober L, Moinard C. Citrulline modulates muscle protein metabolism in old malnourished rats. Am J Physiol Endocrinol Metab. 2006 Sep;291(3):E582-6. Epub 2006 Apr 11.</citation>
    <PMID>16608884</PMID>
  </reference>
  <reference>
    <citation>Faure C, Raynaud-Simon A, Ferry A, Daugé V, Cynober L, Aussel C, Moinard C. Leucine and citrulline modulate muscle function in malnourished aged rats. Amino Acids. 2012 Apr;42(4):1425-33. doi: 10.1007/s00726-011-0841-2. Epub 2011 Feb 23.</citation>
    <PMID>21344178</PMID>
  </reference>
  <reference>
    <citation>Faure C, Morio B, Chafey P, Le Plénier S, Noirez P, Randrianarison-Huetz V, Cynober L, Aussel C, Moinard C. Citrulline enhances myofibrillar constituents expression of skeletal muscle and induces a switch in muscle energy metabolism in malnourished aged rats. Proteomics. 2013 Jul;13(14):2191-201. doi: 10.1002/pmic.201200262. Epub 2013 Jun 10.</citation>
    <PMID>23592530</PMID>
  </reference>
  <reference>
    <citation>Ventura G, Noirez P, Breuillé D, Godin JP, Pinaud S, Cleroux M, Choisy C, Le Plénier S, Bastic V, Neveux N, Cynober L, Moinard C. Effect of citrulline on muscle functions during moderate dietary restriction in healthy adult rats. Amino Acids. 2013 Nov;45(5):1123-31. doi: 10.1007/s00726-013-1564-3. Epub 2013 Aug 3.</citation>
    <PMID>23913268</PMID>
  </reference>
  <reference>
    <citation>The economic burden of lung disease. European white lung book 2013:16-27.</citation>
  </reference>
  <reference>
    <citation>Antonione R. Nutrition in cardiac and pulmonary disease. In Basic in clinical nutrition. Sobotka L. ed. Galen, 4th ed. 485-493.</citation>
  </reference>
  <reference>
    <citation>Jonker R. and al. Whole body de novo ARG production and NO synthesis are reduced in COPD patients. Clin.Nutr. 2013;32(S1):S5-S6.</citation>
  </reference>
  <reference>
    <citation>Coëffier M, Miralles-Barrachina O, Le Pessot F, Lalaude O, Daveau M, Lavoinne A, Lerebours E, Déchelotte P. Influence of glutamine on cytokine production by human gut in vitro. Cytokine. 2001 Feb 7;13(3):148-54.</citation>
    <PMID>11161457</PMID>
  </reference>
  <reference>
    <citation>Lecleire S, Coeffier M, Leblond J, Hubert A, Lemoulan S, Petit A, Ducrotte P, Dechelotte P, Marion R. Modulation of nitric oxide and cytokines production by L-arginine in human gut mucosa. Clin Nutr. 2005 Jun;24(3):353-9.</citation>
    <PMID>15896421</PMID>
  </reference>
  <reference>
    <citation>Hubert-Buron A, Leblond J, Jacquot A, Ducrotté P, Déchelotte P, Coëffier M. Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IkappaBalpha ubiquitination. J Nutr. 2006 Jun;136(6):1461-5.</citation>
    <PMID>16702304</PMID>
  </reference>
  <reference>
    <citation>Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996 Nov;39(5):684-9.</citation>
    <PMID>9026483</PMID>
  </reference>
  <reference>
    <citation>Chan MF. Complications of upper gastrointestinal endoscopy. Gastrointest Endosc Clin N Am. 1996 Apr;6(2):287-303. Review.</citation>
    <PMID>8673329</PMID>
  </reference>
  <reference>
    <citation>Christensen M, Achiam M, Trap R, Støckel M, Rosenberg J, Schulze S. Transnasal gastroscopy. Dan Med Bull. 2000 Jun;47(3):218-20.</citation>
    <PMID>10913986</PMID>
  </reference>
  <reference>
    <citation>Zubarik R, Eisen G, Mastropietro C, Lopez J, Carroll J, Benjamin S, Fleischer DE. Prospective analysis of complications 30 days after outpatient upper endoscopy. Am J Gastroenterol. 1999 Jun;94(6):1539-45.</citation>
    <PMID>10364022</PMID>
  </reference>
  <reference>
    <citation>Dumortier J, Ponchon T, Scoazec JY, Moulinier B, Zarka F, Paliard P, Lambert R. Prospective evaluation of transnasal esophagogastroduodenoscopy: feasibility and study on performance and tolerance. Gastrointest Endosc. 1999 Mar;49(3 Pt 1):285-91.</citation>
    <PMID>10049409</PMID>
  </reference>
  <reference>
    <citation>Lacy PD, Lee JM, O'Morain CA. Temporomandibular joint dislocation: an unusual complication of upper gastrointestinal endoscopy. Am J Gastroenterol. 2000 Dec;95(12):3653-4.</citation>
    <PMID>11151916</PMID>
  </reference>
  <reference>
    <citation>Kise Y, Suzuki R, Shimada H, Tanaka H, Oshiba G, Chino O, Makuuchi H. Idiopathic submucosal hematoma of esophagus complicated by dissecting aneurysm, followed-up endoscopically during conservative treatment. Endoscopy. 2001 Apr;33(4):374-8. Review.</citation>
    <PMID>11315902</PMID>
  </reference>
  <reference>
    <citation>Vu CK, Korman MG, Bejer I, Davis S. Gastrointestinal bleeding after cold biopsy. Am J Gastroenterol. 1998 Jul;93(7):1141-3. Review.</citation>
    <PMID>9672346</PMID>
  </reference>
  <reference>
    <citation>Giudicelli R. [Esophageal perforations. Results of a national survey]. Ann Chir. 1992;46(2):183-7. French.</citation>
    <PMID>1605545</PMID>
  </reference>
  <reference>
    <citation>Giangreco E, D'agate C, Barbera C, Puzzo L, Aprile G, Naso P, Bonanno G, Russo FP, Nicoletti A, Incarbone S, Trama G, Russo A. Prevalence of celiac disease in adult patients with refractory functional dyspepsia: value of routine duodenal biopsy. World J Gastroenterol. 2008 Dec 7;14(45):6948-53.</citation>
    <PMID>19058330</PMID>
  </reference>
  <reference>
    <citation>Heresbach D, Napoléon B. Delchier J.C. and al. Consensus en endoscopie digestive. Acta endo (2009) 39 :206-2011.</citation>
  </reference>
  <reference>
    <citation>Prat F. Recommandations de la SFED 2005 : De la pratique des biopsies oeso-gastro-duodénales.</citation>
  </reference>
  <reference>
    <citation>Boustière C. Endoscopie digestive, antigoagulants, antiagrégants : faut-il encore modifier nos pratiques en 2013 ? Acta endo (2013) 43 :260-265.</citation>
  </reference>
  <reference>
    <citation>Boustière C, Veitch A, Vanbiervliet G, Bulois P, Deprez P, Laquiere A, Laugier R, Lesur G, Mosler P, Nalet B, Napoleon B, Rembacken B, Ajzenberg N, Collet JP, Baron T, Dumonceau JM; European Society of Gastrointestinal Endoscopy. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2011 May;43(5):445-61. doi: 10.1055/s-0030-1256317. Epub 2011 May 4.</citation>
    <PMID>21547880</PMID>
  </reference>
  <reference>
    <citation>Recommandations de bonnes pratiques sur les antiagrégants plaquettaires: prise en compte des risques thrombotique et hémorragique en cas de geste endoscopique HAS-SFED, oct 2012.</citation>
  </reference>
  <reference>
    <citation>Napoléon B, Boneu B, Maillard L, Samama CM, Schved JF, Gay G, Ponchon T, Sautereau D, Canard JM; Board of the French Society for Digestive Endoscopy (SFED). Guidelines of the French Society for Digestive Endoscopy (SFED). Endoscopy. 2006 Jun;38(6):632-8. Epub 2006 Mar 14.</citation>
    <PMID>16586249</PMID>
  </reference>
  <reference>
    <citation>Ventura G, Moinard C, Sinico F, Carrière V, Lasserre V, Cynober L, De Bandt JP. Evidence for a role of the ileum in the control of nitrogen homeostasis via the regulation of arginine metabolism. Br J Nutr. 2011 Jul;106(2):227-36. doi: 10.1017/S0007114511000079.</citation>
    <PMID>22568979</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

